Analysis of HIF-1α and its regulator, PHD2, in retroperitoneal sarcomas: Clinico-pathologic implications

Cancer Biology and Therapy

Volumn 9, Issue 4, 2010, Pages 303-311

  Huang, Jui Han ^a   Lee, Frank S ^a   Pasha, Theresa L ^a   Sammel, Mary D ^a   Karakousis, Giorgos ^a   Xu, George ^a   Fraker, Douglas ^a   Zhang, Paul J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

HIF; Hypoxia; Pathology; PHD2; Retroperitoneal sarcoma; Survival

Indexed keywords

ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROLYL HYDROXYLASE DOMAIN PROTEIN 2; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; EGLN1 PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RETROPERITONEAL SARCOMA; CELL HYPOXIA; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PERITONEUM TUMOR; SARCOMA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELL HYPOXIA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; SARCOMA; YOUNG ADULT;

EID: 77953586434     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.4.10744     Document Type: Article

References (35)

1. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004; 57:1009-14.
2. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009; 19:12-6.
3. Brizel DM, Rosner GL, Prosnitz LR, Dewhirst MW. Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas and lymph node metastases. Int J Radiat Oncol Biol Phys 1995; 32:1121-5.
4. Koch CJ, Evans SM, Lord EM. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N- (2,2,3,3,3- pentafluoropropyl) acetamide]. Br J Cancer 1995; 72:869-74.
5. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56:941-3.
6. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001; 84:1070-5. (Pubitemid 32448504)
7. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008; 30:393-402.
8. Patel SA, Simon MC. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ 2008; 15:628-34.
9. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 2002; 41:79-83. (Pubitemid 34223708)
10. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology 2004; 19:176-82.
11. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5:343-54.
12. Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003; 22:4082-90. (Pubitemid 37021737)
13. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, et al. Differential function of the prolyl hydroxylases PHD1, PHD2 and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004; 279:38458-65. (Pubitemid 39295997)
14. Hewitson KS, Schofield CJ. The HIF pathway as a therapeutic target. Drug Discov Today 2004; 9:704-11.
15. del Peso L, Castellanos MC, Temes E, Martin-Puig S, Cuevas Y, Olmos G, et al. The von Hippel Lindau/ hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem 2003; 278:48690-5. (Pubitemid 41079509)
16. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16:1466-71. (Pubitemid 34686328)
17. Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003; 83:1477-87. (Pubitemid 37267831)
18. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 2001; 8:260-7. (Pubitemid 32294808)
19. Pakos EE, Goussia AC, Tsekeris PG, Papachristou DJ, Stefanou D, Agnantis NJ. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 2005; 25:3591-6. (Pubitemid 41105246)
20. Rathmell WK, Acs G, Simon MC, Vaughn DJ. HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. Anticancer Res 2004; 24:167-9. (Pubitemid 38279704)
21. Ladroue C, Carcenac R, Leporrier M, Gad S, Hello CL, Galateau-Salle F, et al. PHD2 Mutation and Congenital Erythrocytosis with Paraganglioma. N Eng J Med 2008; 359:2685-92.
22. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009; 15:527-38.
23. Lee KA, Lynd JD, O'Reilly S, Kiupel M, McCormick JJ, LaPres JJ. The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential. Mol Cancer Res 2008; 6:829-42.
24. Huang J, Zhao Q, Mooney SM, Lee FS. Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2 and PHD3. J Biol Chem 2002; 277:39792-800. (Pubitemid 35190963)
25. Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer 1984; 53:530-41.
26. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107:1892-5.
27. Percy MJ, Zhao Q, Flores A, Harrison C, Lappin TR, Maxwell PH, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 2006; 103:654-9. (Pubitemid 43153081)
28. Soilleux EJ, Turley H, Tian YM, Pugh CW, Gatter KC, Harris AL. Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology 2005; 47:602-10. (Pubitemid 41775183)
29. Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, Minn H, et al. Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res 2006; 12:1080-7. (Pubitemid 43342495)
30. Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol 2007; 2:145-73.
31. Mazzone M, Dettori D, Oliveira RL, Loges S, Schmidt R, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136:839-51.
32. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007; 17:71-7.
33. Emanuel F, Petricoin I, Espina V, Araujo RP, Midura B, Yeung C, et al. Phosphoprotein pathway mapping: Akt/ mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007; 67:3431-40.
34. Iwenofu O, Goodwin D, Staddon A, Haupt H, Brooks J. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2008; 3:231-7.
35. Merimsky O. Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: an intriguing clinical observation. Int J Mol Med 2004; 14:931-5.